Table 1 Summary of the included records
From: Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review
| No | Authors, year | Type of study | No of Participants | Intervention | Time of evaluation | Outcome |
|---|---|---|---|---|---|---|
| 1 | Cook et al. 2017 [44] | Randomized clinical trial | 17 | Oral Naltrexone (50 mg) for 4 month | 2, 4 and 7 months | 82% of participants completed the 7-month assessment. Alcohol use was reduced substantially in both groups. |
| 2 | Edelman et al. 2019 [45] | Randomized controlled trial | 51 | XR-NTX*, 380 mg (4 mL) injection for 24 weeks | 12, 24,32 and 56 months | The XR-NTX had no effect on ART adherence and HIV markers. XR-NTX was associated with fewer heavy drinking days. |
| 3 | Korthuis et al. 2017b [46] | Pilot study | 29 | XR-NTX injection for 8 month | 16 weeks | Mean days of drinking to intoxication in the past 30 days was decreased. HIV viral suppression was improved |
| 4 | Korthuis et al. 2017a [47] | Pilot/ Feasibility Randomized Trial | 27 | XR-NTX 380 mg for 16 months | 16 weeks | Mean heavy drinking days was decreased. HIV suppression was improved. |
| 5 | Springer et al. 2017 | Randomized, double-blind, placebo-controlled trial | 100 | XR-NTX for 6 month | 6 month | There was no significant differences between groups for drinking outcomes. |
| 6 | Springer et al. 2018 [48] | Double blind randomized placebo-controlled trial | 100 | XR-NTX for 6 month | 6 month | The XR-NTX has improved or maintain the viral suppression (VS). |
| 7 | Hu et al. 2013 [49] | Double-blind, randomized controlled trial | 19 | Oral Naltrexone (50 mg) for 4 month | 2, 4 and 7 months | Average daily alcohol consumption was reduced. |